Iterion Therapeutics

Iterion is proud to continue sponsoring National Pediatric Cancer Foundation.

Exciting times for us!

Iterion Therapeutics Confirms Safety of Tegavivint Following Completion of Enrollment in Phase 1/2a Expansion Study in Patients with Desmoid Tumors /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that...

https://www.businesswire.com/news/home/20181205005630/en/Iterion-Therapeutics-Initiates-Phase-Clinical-Study-Tegavivint

Iterion Therapeutics Initiates Phase I Clinical Study of Tegavivint in Patients with Desmoid Tumors Iterion Therapeutics, formerly known as Beta Cat Pharmaceuticals, today announced that it has initiated a multi-center Phase I clinical study of Tegav